Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 14:01 save search
AnaptysBio Reports Positive Topline Data from GALLOP Phase 2 Clinical Trial of Imsidolimab in Moderate-to-Severe Generalized Pustular Psoriasis (GPP)
Published: 2020-10-13 (Crawled : 14:01) - ir.anaptysbio.com
ANAB | $19.865 0.18% 0.18% 290K
|
Health Technology
|
| O: 1.01%
H: 5.5%
C: 4.96%
phase 2 positive trial topline psoriasis
Acer Therapeutics Announces Topline Results from its Bioequivalence Trial of ACER-001 Compared to BUPHENYL® Under Fed Conditions
Published: 2021-02-11 (Crawled : 14:01) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 1.47%
H: 10.6%
C: -3.86%
results trial topline
Vaxart Announces Positive Preliminary Data from Phase 1 Clinical Trial Evaluating Its Oral COVID-19 Tablet Vaccine Candidate
Published: 2021-02-03 (Crawled : 14:01) - globenewswire.com
VXRT | News | $0.7652 -9.15% -10.08% 1.9M
|
Health Technology
|
| O: -53.56%
H: 17.58%
C: -9.09%
covid positive vaccine trial phase 3 phase 1 phase 2
Phathom Pharmaceuticals Announces Completion of Patient Enrollment in Pivotal Phase 3 Helicobacter pylori (H. pylori) Trial
Published: 2021-01-19 (Crawled : 14:01) - globenewswire.com
PHAT | $8.98 -5.27% -5.57% 590K
|
Health Technology
|
| O: 1.6%
H: 1.49%
C: 1.02%
phase 3 trial enroll
Arcutis Initiates Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast Cream (ARQ-151) as a Potential Treatment for Atopic Dermatitis
Published: 2021-01-13 (Crawled : 14:01) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: -0.92%
H: 4.67%
C: 0.26%
dermatitis phase 3 trial treatment potential atopic dermatitis
Cellectar Initiates Pivotal Trial of CLR 131 in Waldenstrom’s Macroglobulinemia
Published: 2021-01-12 (Crawled : 14:01) - globenewswire.com
CLRB | $3.02 -0.66% -0.66% 810K
|
Health Technology
|
| O: 4.04%
H: 1.94%
C: -1.94%
trial
Acer Therapeutics Announces Full Enrollment of Pivotal Bioequivalence Trial of ACER-001 for Urea Cycle Disorders
Published: 2020-12-22 (Crawled : 14:01) - globenewswire.com
ACER | $0.9 -3.61% 420K
|
Health Technology
|
| O: 0.38%
H: 0.75%
C: -3.01%
urea trial enroll
Zealand Pharma announces data from the first phase 3-trial with dasiglucagon in Congenital Hyperinsulinism (CHI)
Published: 2020-12-15 (Crawled : 14:01) - globenewswire.com
ZEAL | News | $17.59 1.21% -4.21%
|
Health Technology
|
| O: -10.58%
H: 2.98%
C: 2.97%
insulin phase 3 trial pharma
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
Published: 2020-12-11 (Crawled : 14:01) - globenewswire.com
SLS | $1.525 0.33% 0.33% 1.8M
|
Health Technology
|
| O: -24.63%
H: 8.19%
C: -37.11%
positive trial phase 2
Arcutis Announces Last Patient Completes Final Study Visit in DERMIS-1 and DERMIS-2 Pivotal Phase 3 Clinical Trials Evaluating ARQ-151 (Topical Roflumilast Cream) as a Potential Treatment for Plaque Psoriasis
Published: 2020-12-07 (Crawled : 14:01) - globenewswire.com
ARQT | $9.09 -3.81% -3.96% 4.5M
|
Health Technology
|
| O: 0.88%
H: 2.25%
C: 1.03%
phase 3 trial potential psoriasis plague
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.